18544172

Source:http://linkedlifedata.com/resource/pubmed/id/18544172

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0036525, umls-concept:C0087111, umls-concept:C0332281, umls-concept:C0449258, umls-concept:C1414313, umls-concept:C1516213, umls-concept:C1517050, umls-concept:C1522484, umls-concept:C1527249, umls-concept:C1882417
pubmed:dateCreated	2008-6-20
pubmed:abstractText	Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants of cetuximab activity.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-11252954, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-14993230, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15118073, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15118125, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15269308, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15269313, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15329413, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15625347, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15677699, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15832190, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15837620, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-15863375, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-16098254, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-16278407, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-16324192, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-16618717, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-16943533, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17050875, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17363584, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17375050, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17470858, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17575224, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17664471, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17664472, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-17940504, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-7937865, http://linkedlifedata.com/resource/pubmed/commentcorrection/18544172-8466482
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100967800
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor, http://linkedlifedata.com/resource/pubmed/chemical/cetuximab, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
pubmed:status	MEDLINE
pubmed:issn	1471-2407
pubmed:author	pubmed-author:AyadiMounayM, pubmed-author:BertucciFrançoisF, pubmed-author:BirnbaumDanielD, pubmed-author:BorgJean-PaulJP, pubmed-author:DelperoJean-RobertJR, pubmed-author:EsterniBenjaminB, pubmed-author:EsteyriesSéverineS, pubmed-author:GonçalvesAnthonyA, pubmed-author:LagardeArnaudA, pubmed-author:LelongBernardB, pubmed-author:MongesGenevièveG, pubmed-author:OlschwangSylvianeS, pubmed-author:Taylor-SmedraBrynnB, pubmed-author:TurriniOlivierO, pubmed-author:ViensPatriceP, pubmed-author:ViretFrédéricF
pubmed:issnType	Electronic
pubmed:volume	8
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	169
pubmed:dateRevised	2009-11-19
pubmed:meshHeading	pubmed-meshheading:18544172-Adult, pubmed-meshheading:18544172-Aged, pubmed-meshheading:18544172-Antibodies, Monoclonal, pubmed-meshheading:18544172-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18544172-Camptothecin, pubmed-meshheading:18544172-Colorectal Neoplasms, pubmed-meshheading:18544172-Disease-Free Survival, pubmed-meshheading:18544172-Exons, pubmed-meshheading:18544172-Female, pubmed-meshheading:18544172-Gene Dosage, pubmed-meshheading:18544172-Genes, ras, pubmed-meshheading:18544172-Humans, pubmed-meshheading:18544172-In Situ Hybridization, Fluorescence, pubmed-meshheading:18544172-Male, pubmed-meshheading:18544172-Middle Aged, pubmed-meshheading:18544172-Mutation, pubmed-meshheading:18544172-Neoplasm Metastasis, pubmed-meshheading:18544172-Polymorphism, Genetic, pubmed-meshheading:18544172-Protein Structure, Tertiary, pubmed-meshheading:18544172-Receptor, Epidermal Growth Factor, pubmed-meshheading:18544172-Retrospective Studies, pubmed-meshheading:18544172-Treatment Outcome
pubmed:year	2008
pubmed:articleTitle	A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment.
pubmed:affiliation	Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France. goncalves.anthony2@orange.fr
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't